Evidence map›Paper›PMID 28338897›Full record

ArticleSchizophrenia bulletin2017

Specialized Information Processing Deficits and Distinct Metabolomic Profiles Following TM-Domain Disruption of Nrg1.

Colm M P O'Tuathaigh, Naina Mathur, Matthew J O'Callaghan, Lynsey MacIntyre, Richard Harvey, Donna Lai, John L Waddington, Benjamin S Pickard, David G Watson, Paula M Moran

Open access · bronzeAbstract read
In one paragraph

Article in Schizophrenia bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Metabolomics: A Powerful Tool to Understand the Schizophrenia Biology.Advances in experimental medicine and biology · 2022
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Colm M P O'TuathaighSchool of Medicine, University College Cork, Cork, Ireland.
Naina MathurSchool of Psychology, University of Nottingham, Nottingham, UK.
Matthew J O'CallaghanSchool of Psychology, University of Nottingham, Nottingham, UK.
Lynsey MacIntyreStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
Richard HarveyVictor Chang Cardiac Research Institute, Sydney, Australia.
Donna LaiVictor Chang Cardiac Research Institute, Sydney, Australia.
John L WaddingtonMolecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Benjamin S PickardStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
David G WatsonStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
Paula M MoranSchool of Psychology, University of Nottingham, Nottingham, UK.
University of Nottingham · GBUniversity of Strathclyde · GBVictor Chang Cardiac Research Institute · AUSoochow University · CNUniversity College Cork · IE

Funding

Wellcome TrustWellcome Trust WT0845921Z
6 · The paper itself

Abstract

Although there is considerable genetic and pathologic evidence for an association between neuregulin 1 (NRG1) dysregulation and schizophrenia, the underlying molecular and cellular mechanisms remain unclear. Mutant mice containing disruption of the transmembrane (TM) domain of the NRG1 gene constitute a heuristic model for dysregulation of NRG1-ErbB4 signaling in schizophrenia. The present study focused on hitherto uncharacterized information processing phenotypes in this mutant line. Using a mass spectrometry-based metabolomics approach, we also quantified levels of unique metabolites in brain. Across 2 different sites and protocols, Nrg1 mutants demonstrated deficits in prepulse inhibition, a measure of sensorimotor gating, that is, disrupted in schizophrenia; these deficits were partially reversed by acute treatment with second, but not first-, generation antipsychotic drugs. However, Nrg1 mutants did not show a specific deficit in latent inhibition, a measure of selective attention that is also disrupted in schizophrenia. In contrast, in a "what-where-when" object recognition memory task, Nrg1 mutants displayed sex-specific (males only) disruption of "what-when" performance, indicative of impaired temporal aspects of episodic memory. Differential metabolomic profiling revealed that these behavioral phenotypes were accompanied, most prominently, by alterations in lipid metabolism pathways. This study is the first to associate these novel physiological mechanisms, previously independently identified as being abnormal in schizophrenia, with disruption of NRG1 function. These data suggest novel mechanisms by which compromised neuregulin function from birth might lead to schizophrenia-relevant behavioral changes in adulthood.

Indexed as

Memory, EpisodicMetabolic Networks and PathwaysAnimalsAntipsychotic AgentsAttentionBehavior, AnimalBrainDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLMice, TransgenicNeural InhibitionNeuregulin-1Antipsychotic AgentsNeuregulin-1Nrg1 protein, mouseantipsychoticscholinecognitionlipidsmetabolomemutant phenotypeneuregulinprepulse inhibitionschizophrenia

Identifiers

PMID28338897
PMCPMC5581893
OpenAlexW2585880673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.